Immunocine Cancer Center

Your greatest defense is within you. Immunocine was founded to bring revolutionary immunotherapy to cancer patients who are not eligible for FDA clinical trials. Our proprietary treatment, Immunocine Dendritic Cell Therapy (IDCT), “double loads” a patient’s dendritic cells with their own cancer cells. This process mimics a viral infection and triggers a powerful, targeted immune response. Backed by 16 years of research and ongoing FDA trials, IDCT offers a less invasive, highly precise option for treating multiple types of cancer. Visit our website to see if you’re eligible to apply for treatment.